Jan 30 (Reuters) - Vertex Pharmaceuticals said on Tuesday its experimental drug for treating post-surgical pain succeeded in a pair of late-stage trials, a major milestone in the company's decades-long efforts to bring a non-opioid pain medicine to market. (Reporting by Leroy Leo and Sriparna Roy in Bengaluru; Editing by Sriraj Kalluvila and Bill Berkrot)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
A month after a higher state minimum wage for fast-food workers went into effect, consumers picking up burgers and burritos at chains in the Golden State grapple with prices rising at a faster clip than in other states.
In addition to economic and earnings news, inflation and geopolitical worries will have roles to play.
Nancy Pelosi's husband Paul Pelosi uses an investing strategy that lowers upfront costs.
The $50 million purchase could turn into Nvidia's biggest investment.
These two dividend payers have historically high yields and attractive businesses, even though there are some headwinds to deal with.
The tobacco giant will soon be allowed to sell a proven product in a proven market.
Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.
This little-known software stock could soar as businesses spend more on generative artificial intelligence.
After a bounceback week for stocks, a Fed meeting, jobs report, and a busy week of corporate earnings are set to greet investors.